Trials / Completed
CompletedNCT00469183
Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma
An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.
Detailed description
Same as above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05% | Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2007-05-04
- Last updated
- 2022-07-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00469183. Inclusion in this directory is not an endorsement.